摘要
近10年来，随着对银屑病免疫学机制和易感基因研究的不断深入，越来越多针对关键发病环节的靶向性生物制剂被研发出来用于控制这-顽疾。根据作用机制的不同，银屑病生物制剂主要分为阻断共刺激信号和抑制炎症介质两种。其中，肿瘤坏死因子α、白介素12及白介素23为其主要的炎症介质靶点。对目前欧美已经批准上市和尚未批准，但较有潜力的多种银屑病生物制剂的作用机制、临床疗效及安全性进行阐述。
With the progress in the understanding of immunological mechanisms and susceptibility genes of psoriasis, an increasing number of targeted biological agents have been developed over the past decade. According to the mechanism of action, these agents are mainly divided into two groups, including costimulatory signal-blocking agents and inflammatory mediator-inhibiting agents. Inflammatory mediators targeted by these agents mainly include tumor necrosis factor α, interleukin-12 and interleukin-23. This review introduces the mechanism, clinical efficacy and safety of many biological agents which have been approved or unapproved but have shown vast potential for treating psoriasis in Europe and America.
出处
《国际皮肤性病学杂志》
2012年第6期366-369,共4页
International Journal of Dermatology and Venereology
